Study Finds Spironolactone Increases Hospitalizations in Heart Failure Patients at ACC.26 Conference
• The SPIRIT-HF study, presented at ACC.26 in New Orleans (March 28-30, 2026), found that spironolactone increased hospitalizations and serious adverse events in patients with HFpEF (heart failure with preserved ejection fraction) or HFmrEF (mildly reduced ejection fraction). • Results raise significant safety questions about the drug's efficacy in these patient populations, potentially challenging current treatment protocols. • The findings were presented to cardiologists and cardiovascular specialists at the American College of Cardiology's annual conference, the largest gathering of heart disease specialists.
acc.org